Research and Markets: Nicholas Hall's Global Cough, Cold & Allergy Review: Sore Throat Remedies & Medicated Confectionery

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/c74f2b/nicholas_halls_gl) has announced the addition of the "Nicholas Hall's Global Cough, Cold & Allergy Review" report to their offering.

This essential report is the ideal guide to CCA brands and marketers across leading developed and emerging markets, focusing on core trends and exciting developments. CCA categories covered include Cough remedies, Systemic cold & flu, topical decongestants, chest rubs & inhalants, sore throat remedies & medicated confectionery, allergy remedies and asthma remedies.

The second-largest OTC category - 22% of global turnover

CCA remedies form the second-largest major OTC category, generating 22% of global OTC turnover and consistently outperforming the overall market in terms of growth. In 2009, CCA sales rose by 5.5%, with the H1N1 flu virus scare driving sales in many markets, while cough remedies and topical decongestants were the best-performing categories globally. But despite many positives, this is a fiercely competitive market that faces a number of stern challenges.

Sales have been hit by reviews into the safety of children's cough & cold remedies, prompting voluntary recalls or forced withdrawals/reclassifications in key markets. Systemic cold & flu remedies remain beset by ingredient problems as well as facing increasing pressure from immunity-boosting VMS products positioned to ward off colds. Cough remedies in the US were revitalised by the rise of Mucinex, but with sales slowing down and generic competition preparing to take a further bite, new sources of growth are needed.

The sizeable sore throat remedies & medicated confectionery category continues to grow, but a lack of innovation may take its toll. Growth of allergy remedies almost flatlined in 2009, with previous blockbusters Claritin and Zyrtec suffering declines. Topical decongestants offered a bright spot, with non-medicated saline sprays proving popular (especially in the wake of safety concerns over children's cough & cold products).

Innovations such as thin strips, orodispersible microgranules and nasal swabs have moved the CCA market forward, but more is needed to sustain sales in the face of encroaching generics and me-too products. But where will this innovation come from? Will potential future switches like Tamiflu, Singulair and Clarinex/Aerius have much impact? Can Mucinex have the same impact in Europe as it had in the US? What does the rising popularity of homeopathic options (notably in France, Germany and the US) mean for traditional CCA products?

This comprehensive report scrutinises CCA brands and marketers in the leading developed and emerging markets. Strategic analysis defines and explores the trends and developments affecting OTC cough, cold & allergy globally and in individual countries. Each country profile includes an overview of key trends, considered analysis by category, and an evaluation of the prospects for CCA in the future.

Products Mentioned:

  • Arbidol
  • Bai Jia Hei
  • Claritin (and Clarinex / Aerius)
  • Mucinex
  • Otrivin
  • Strepsils
  • Tamiflu
  • Theraflu
  • Vicks
  • Zyrtec

For more information visit http://www.researchandmarkets.com/research/c74f2b/nicholas_halls_gl.



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Retail  Food/Beverage

MEDIA:

Logo
 Logo

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.